08 September 2020 : Original article
Prediction of Liver Prognosis from Pre-Transplant Renal Function Adjusted by Diuretics and Urinary Abnormalities in Adult-to-Adult Living Donor Liver Transplantation
Mineaki Kitamura1ABCDEFG*, Masaaki Hidaka2ABDE, Kumiko Muta1BC, Satoshi Miuma3BDE, Hisamitsu Miyaaki3CD, Mitsuhisa Takatsuki2D, Kazuhiko Nakao3D, Susumu Eguchi2DE, Hiroshi Mukae4D, Tomoya Nishino1ACDEDOI: 10.12659/AOT.924805
Ann Transplant 2020; 25:e924805
Table 2 Patient characteristics according to change in renal function.
| Improved (N=65) | Deteriorated (N = 127) | P value | |
|---|---|---|---|
| Recipient age (years) | 53.8 (11.4) | 53.7 (11.8) | 0.92 |
| Recipient sex, male (%) | 47.7% | 61.4% | 0.09 |
| Donor age (years) | 37.5 (12.5) | 39.0 (12.9) | 0.51 |
| MELD score | 19.0 (8.1) | 17.4 (7.3) | 0.24 |
| Cirrhosis due to hepatitis B virus (%) | 13.9% | 19.7% | 0.32 |
| Cirrhosis due to hepatitis C virus (%) | 38.5% | 34.7% | 0.60 |
| Hepatocellular carcinoma | 35.3% | 46.5% | 0.14 |
| Diabetes | 24.6% | 21.3% | 0.60 |
| Hypertension | 15.4% | 15.0% | 0.94 |
| Chronic kidney disease | 42.9% | 25.0% | <0.001 |
| Ascites (+) | 58.5% | 48.8% | 0.20 |
| Diuretics | 75.4% | 58.8% | 0.006 |
| Hemoglobin (g/dL) | 9.8 (2.0) | 10.8 (2.4) | 0.01 |
| Platelet (×10) (/μL) | 62 (41–97) | 62 (41–95) | 0.32 |
| Prothrombin time (%) | 52.0 (19.9) | 52.6 (17.3) | 0.56 |
| Total bilirubin (mg/dL) | 3.4 (1.9–8.2) | 3.4 (1.6–7.5) | 0.78 |
| Aspartate aminotransferase (IU/L) | 58 (33–74) | 57 (39–84) | 0.44 |
| Alanine aminotransferase (IU/L) | 30 (20–62) | 37 (26–62) | 0.07 |
| Albumin (g/dL) | 2.87 (0.61) | 2.99 (0.59) | 0.10 |
| Urinary abnormalities | 30.5% | 21.7% | 0.20 |
| Proteinuria >1+ | 8.5% | 9.2% | 0.87 |
| Hematuria >1+ | 26.3% | 17.7% | 0.15 |
| Data are represented as medians (interquartile ranges), percentages (%) or means (standard deviations) and collected pre- or at transplantation. MELD – model for end-stage liver disease. | |||